Skip to main content
Caplight Logo









EVIIVE AG

EVIIVE AG

Private
ZurichHealthcare & Life Scienceshttps://eviive.ch/

Last Round

Accelerator

Dec 27, 2024

Total Funding Raised

$462,800

Company Overview

EVIIVE AG is a biotech company developing a next-generation liquid biopsy platform using extracellular vesicle (EV) analysis and machine learning to guide personalized treatment decisions in immuno-oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Revenue Share

AI Layer

Application

Keywords

companion diagnosticsCDxliquid biopsybiomarker discoverypatient stratificationimmuno-oncologyextracellular vesicle analysisprecision diagnosticsAI diagnosticsimmunotherapy responseflow cytometrymulti-omics analysistherapeutic target discoveryclinical trial supportmelanoma diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EVIIVE AG Comparables

Compare EVIIVE AG with similar companies based on industry and business-model similarity.

EVIIVE AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mursla Bio
77%
Exosomics S.p.A.
74%
Mercy BioAnalytics
70%

EVIIVE AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorDec 27, 2024
GrantOct 1, 2024
GrantNov 1, 2023
GrantSep 1, 2023
GrantDec 16, 2022

Key People

Founding team and executive leadership

Kevin Yim

Co-Founder & CEO

Founding Team

EVIIVE AG Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors increased 429% MoM.

  • Nov 7, 2025

    Monthly visitors increased 147% MoM.

EVIIVE AG Filings

Explore SEC and related filing metadata, where available.

EVIIVE AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about EVIIVE AG's valuation, stock price, and market status.

Is EVIIVE AG a public or private company?

EVIIVE AG is a private company.

What is the current stock price of EVIIVE AG?

EVIIVE AG is a private company with no public stock price. No recent secondary market data is available.

How much is EVIIVE AG worth (valuation)?

Valuation information for EVIIVE AG is not publicly available.

Can I buy EVIIVE AG stock?

EVIIVE AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was EVIIVE AG's last funding round?

EVIIVE AG's most recent funding round was Accelerator on December 27, 2024.

Who are the main investors in EVIIVE AG?

Key investors in EVIIVE AG include Gebert Rüf Stiftung, Werner Siemens-Stiftung, Swiss National Science Foundation, Innosuisse, University of Zurich.

Will EVIIVE AG IPO soon?

No public IPO plans have been announced for EVIIVE AG.

How can I track EVIIVE AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EVIIVE AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersZurich
Employee Range4
Year Founded2022
Last FundingDec 27, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?